北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学深圳医院  > 期刊论文
学科主题: 临床医学
题名:
A Population-Based Clinical Trial Comparing Endocervical High-Risk HPV Testing Using Hybrid Capture 2 and Cervista From the SHENCCAST II Study
作者: Belinson, Jerome L.1,5; Wu, Ruifang2; Belinson, Suzanne E.1; Qu, Xinfeng3; Yang, Bin4; Du, Hui2; Wu, Ruosong3; Wang, Chun2; Zhang, Lijie2; Zhou, Yanqiu2; Liu, Ying2; Pretorius, Robert G.6
关键词: Hybrid Capture 2 ; Cervista ; Cervical cancer screening ; Human papillomavirus ; HPV
刊名: AMERICAN JOURNAL OF CLINICAL PATHOLOGY
发表日期: 2011-05-01
DOI: 10.1309/AJCPKA6ATAPBZ6JQ
卷: 135, 期:5, 页:790-795
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pathology
研究领域[WOS]: Pathology
关键词[WOS]: GRADE CERVICAL LESIONS ; HUMAN-PAPILLOMAVIRUS ; CANCER ; WOMEN ; PERFORMANCE ; CYTOLOGY ; DETECT ; HR
英文摘要:

Our objective was to directly compare the accuracy of the high-risk human papillomavirus (HPV) assays, Hybrid Capture 2 (hc2; Qiagen, Gaithersburg, MD) and Cervista (Hologic, Bedford, MA), in diagnosing cervical intraepithelial neoplasia (CIN) 3 or worse (cancer).

A population-based, cross-sectional study (The Shenzhen Cervical Cancer Screening Trial II) was conducted in Guangdong Province in China. Three high-risk HP V assays, self and direct cervical sampling and cytology, were studied. Abnormal results on any of 6 study tests (33%) resulted in referral to colposcopy. At colposcopy, every patient had at least 5 cervical biopsy specimens obtained.

For 8,556 women between the ages of 25 and 59 years (mean, 38.9 years), the rate for CIN 3 or worse was 1.6% (141/8,556). The sensitivity (confidence interval) values for CIN 3 or worse were 97.9% (94.0%-99.6%) and 95.1% (90.0%-98.0%) for hc2 and Cervista, respectively (P > .05). The specificity (confidence interval) values were 87.8% (87.1%-88.5%) and 90.3% (89.6%-90.9%), respectively P < .05).

Differences in accuracy in diagnosing CIN 3 or worse with the hc2 and Cervista tests are minor and result from the decisions made in selecting the cut points.

语种: 英语
项目资助者: Preventive Oncology International, Cleveland Heights, OH ; Hologic, Bedford, MA ; Shenzhen Female Doctors Association, Shenzhen, Peoples Republic of China
WOS记录号: WOS:000289743400019
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58930
Appears in Collections:北京大学深圳医院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Prevent Oncol Int, Cleveland Hts, OH USA
2.Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China
3.Royal Ladies Clin, Shenzhen, Peoples R China
4.Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
5.Cleveland Clin, Dept Obstet & Gynecol, Cleveland, OH 44106 USA
6.Kaiser Permanente, Dept Obstet & Gynecol, Fontana, CA USA

Recommended Citation:
Belinson, Jerome L.,Wu, Ruifang,Belinson, Suzanne E.,et al. A Population-Based Clinical Trial Comparing Endocervical High-Risk HPV Testing Using Hybrid Capture 2 and Cervista From the SHENCCAST II Study[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY,2011,135(5):790-795.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Belinson, Jerome L.]'s Articles
[Wu, Ruifang]'s Articles
[Belinson, Suzanne E.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Belinson, Jerome L.]‘s Articles
[Wu, Ruifang]‘s Articles
[Belinson, Suzanne E.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace